Bioanalytical approaches to quantify "total" and "free" therapeutic antibodies and their targets: technical challenges and PK/PD applications over the course of drug development.
The predominant driver of bioanalysis in supporting drug development is the intended use of the data. Ligand-binding assays (LBA) are widely used for the analysis of protein biotherapeutics and target ligands (L) to support pharmacokinetics/pharmacodynamics (PK/PD) and safety assessments. For monoclonal antibody drugs (mAb), in particular, which non-covalently bind to L, multiple forms of mAb and L can exist in vivo, including free mAb, free L, and mono- and/or bivalent complexes of mAb and L. Given the complexity of the dynamic binding equilibrium occurring in the body after dosing and multiple sources of perturbation of the equilibrium during bioanalysis, it is clear that ex vivo quantification of the forms of interest (free, bound, or total mAb and L) may differ from the actual ones in vivo. LBA reagents and assay formats can be designed in principle to measure the total or free forms of mAb and L. However, confirmation of the forms being measured under the specified conditions can be technically challenging. The assay forms and issues must be clearly communicated and understood appropriately by all stakeholders as the program proceeds through the development process. This paper focuses on monoclonal antibody biotherapeutics and their circulatory L that are either secreted as soluble forms or shed from membrane receptors. It presents an investigation into the theoretical and practical considerations for total/free analyte assessment to increase awareness in the scientific community and offer bioanalytical approaches to provide appropriate PK/PD information required at specific phases of drug development.
Amgen Inc, One Amgen Center Drive, Thousand Oaks, California 91320, USA. jwlee@amgen.com
Jean W
JW
Lee
Marian
M
Kelley
Lindsay E
LE
King
Jihong
J
Yang
Hossein
H
Salimi-Moosavi
Meina T
MT
Tang
Jian-Feng
JF
Lu
John
J
Kamerud
Ago
A
Ahene
Heather
H
Myler
Cindy
C
Rogers
D000465:Algorithms; D000818:Animals; D000911:Antibodies, Monoclonal / Q000032:analysis / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D015195:Drug Design; D006801:Humans; D008024:Ligands; D011955:Receptors, Drug / Q000187:drug effects
D000911:Antibodies, Monoclonal; D008024:Ligands; D011955:Receptors, Drug
J Pharm Biomed Anal. 2008 Nov 4;48(3):897-901
18760557
Anal Chem. 2008 Mar 1;80(5):1737-45
18225864
J Immunol Methods. 2004 Jun;289(1-2):97-109
15251416
J Biol Chem. 1996 Dec 13;271(50):31894-902
8943233
Pharm Res. 2003 Nov;20(11):1885-900
14661937
Anal Chem. 2008 Jun 1;80(11):4200-7
18465883
Anal Chem. 2008 Feb 15;80(4):1290-6
18217771
Br J Clin Pharmacol. 2009 Jul;68(1):61-76
19660004
Blood Transfus. 2007 Nov;5(4):227-40
19204779
Bioanalysis. 2010 Jun;2(6):1125-40
21083212
Retina. 2006 Oct;26(8):871-6
17031285
Pharm Res. 2006 Feb;23(2):312-28
16397743
Mol Cell Biochem. 1975 Jun 30;7(3):157-74
168483
J Pharmacol Toxicol Methods. 2009 May-Jun;59(3):171-80
19258043
J Pharm Biomed Anal. 2010 Apr 6;51(5):1128-33
20022440
J Pharmacol Exp Ther. 2010 Apr;333(1):2-13
20089807
J Immunol Methods. 2007 Aug 31;325(1-2):127-39
17651747
J Exp Med. 2009 May 11;206(5):1029-36
19364880
Anal Chem. 2008 Aug 15;80(16):6159-67
18642877
Ther Drug Monit. 2009 Oct;31(5):597-601
19730278
Clin Exp Metastasis. 2002;19(8):651-63
12553370
Clin Pharmacol Ther. 2008 Nov;84(5):548-58
18784655
Analyst. 2009 May;134(5):825-34
19381370
Anal Chem. 2008 Apr 15;80(8):2688-93
18348541
J Pharm Sci. 2004 Nov;93(11):2645-68
15389672